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Abstract
Background: There are clinical situations (CS) in which the use of somatostatin analogs (SSAs) in patients with
neuroendocrine tumors (NET) is controversial due to lack of evidence. A Delphi study was conducted to develop
common treatment guidelines for these CS, based on clinical practice and expert opinion of Spanish oncologists.
Methods: A scientific committee identified 5 CS with a common core (c-c) [non-functioning NET, not susceptible of
surgery/locoregional therapy, Ki67 < 10 % (except for CS5: >10 %), ECOG ≤ 2], and controversy regarding use of
SSAs, and prepared a Delphi questionnaire of 48 treatment statements. Statements were rated on a 1 (completely
disagree) to 9 (completely agree) scale. Responses were grouped by tertiles: 1–3: Disagreement, 4–6: Neutral, 7–9:
Agreement. Consensus was reached when the responses of ≥2/3 participants were located in the same tertile as
the median value of all reported responses for that statement.
Results: Sixty five (81.2 %) of 80 invited oncologists with experience in the management of NETs answered a first
round of the questionnaire and 57 (87.7 %) of those 65 answered a second round (mean age 43.5 years; 53.8 %
women; median time of experience 9 years). Consensus was obtained in 42 (36 agreement and 6 disagreement) of
the 48 statements (87.5 %). Regarding CS1 (Enteropancreatic NET, c-c, non-progressive in the last 3–6 months),
overall, SSA treatment is recommended (a wait and see approach is anecdotal and reserved for fragile patients or
with low tumor load or ki-67 < 2 %); CS2 (Pancreatic NET, c-c), overall, SSA monotherapy is recommended, except
when high tumor load or tumor progression exists, where combination therapy would be considered; CS3
[Gastroenteropancreatic (GEP)-NET, c-c, in treatment with anti-proliferative dose of SSA and progressing], overall,
SSA maintenance is recommended at the time of progression, with or without adding molecular targeted drugs;
CS4 (GEP-NET, c-c, and negative octreoscan®), SSA in monotherapy is only considered in low-risk patients (low
tumor load and Ki-67 < 5 %); CS5 [GEP-NET, c-c (ki67 > 10 %), and positive octreoscan®], monotherapy with SSA is
mainly considered in patients with comorbidities.
Conclusion: Several recommendations regarding use of SSAs in controversial NET CS were reached in consensus
and might be considered as treatment guideline.
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Background
Neuroendocrine tumors (NETs) are neoplasms that
originate from the peripheral neuroendocrine cell sys-
tem and lungs, and are most frequently located in the
gastroenteropancreatic (GEP) system [1]. GEP-NETs
may present as hormonally functioning or nonfunc-
tioning tumors and have distinct clinical features based
on their site of origin [2]. The age-adjusted incidence
of GEP-NETs in the United States was 3.65/100,000/
year between 2003 and 2007 [3], while data from
Europe (United Kingdom) regarding gastrointestinal
NETs showed an age-adjusted incidence of 1.32 and
1.33 in males and females, respectively, between 2000
and 2006 [4]. Overall, the age-adjusted incidence of
NETs has increased 3.65-fold in the United States and
up to 4.8-fold in the United Kingdom over the past
four decades. Regarding life expectancy, the median
survival of registered GEP-NETs in Spain was shown
to be 12 years (75 % at 5 years) [5].
Somatostatin analogues (SSAs) have been mainly used
in functioning tumors to improve the symptoms of
carcinoid syndrome or symptoms of other functional
NETs [6, 7]; however, their antiproliferative properties
are beneficial in both functioning and non-functioning
tumors [8–10]. The randomized, double-blind, placebo-
controlled PROMID study [11], was the first study
reporting an antiproliferative effect of the SSA octreotide
long-acting repeatable (LAR) in patients with metastatic
G1 midgut NETs, prolonging time to tumor progression
as compared to placebo in patients with functionally
active and inactive tumors. Recently, the randomized,
double-blind, placebo-controlled CLARINET study
[12], conducted in patients with advanced grade 1 or 2
(Ki67 < 10 %) NETs originating in the pancreas, midgut
or hindgut, or of unknown origin, showed that treat-
ment with the SSA lanreotide significantly prolonged
progression-free survival (PFS) compared with placebo,
regardless of the hepatic tumor burden. The antitumor
effects of SSAs can be direct, via the interaction with
somatostatin receptors, or indirect, by a complex
mechanism leading to immune system modulation,
apoptosis induction, and angiogenesis inhibition [13].
Clinical guidelines can help in the management of
NET patients [14–21]. However, there are still clinical
situations (CS) in which the use of SSAs is controver-
sial due to lack of evidence. It is recognized that
clinical experience and expert opinion could help
establish recommendations for the management of
these situations and thus, the NETPraxis program was
created.
The NETPraxis program aimed to develop common
treatment guidance for controversial CS regarding the
use of SSAs, based on clinical practice experience and
expert opinion of Spanish oncologists.
Methods
A scientific committee of 6 Spanish oncologists with
experience in the management of NETs identified 5 CS
with a common core [non-functioning NET, not suscep-
tible of surgery/locoregional therapy, Ki67 < 10 % (except
for CS5: Ki67 > 10 %), ECOG ≤ 2], and controversy regard-
ing pharmacologic treatment with SSAs: CS1 (Enteropan-
creatic NET, common core, non-progressive in the last 3–
6 months), wait and see or SSA?; CS2 (Pancreatic NET,
common core), initial SSA, molecular targeted drugs
(MTD) or chemotherapy?; CS3 [GEP-NET, common core,
in treatment with anti-proliferative dose of SSA and pro-
gressing], maintain SSA?; CS4 (GEP-NET, common core
and negative octreoscan®), initial SSA?; CS5 [GEP-NET,
common core (ki67 > 10 %), initial SSA?.
Supported by related bibliography, these 5 CS were dis-
cussed in 13 local meetings among a total of 66 Spanish
oncologists, including the members of the scientific com-
mittee. Based on the results of the discussions, the scien-
tific committee prepared a Delphi questionnaire of 48
statements regarding treatment with SSAs, divided into
blocks for each of the 5 CS (see tables in the Results
section for the whole list of statements; the references used
to discuss each of the 5 CS in the local meetings are con-
tiguous to the corresponding CS in the tables). The Delphi
method is a widely accepted technique for reaching a con-
sensus among a panel of experts [22]. The experts respond
anonymously to at least two rounds of a questionnaire and
are provided with a summary of all responses after each
round [23]. The experts may then revise their earlier
responses in light of those by other members.
Eighty Spanish oncologists with proven experience
in the treatment of NETs (>5 years), including those
participating in the meetings, were invited to answer
the first round of Delphi questionnaire. From October
to November 2015, 65 (81.2 %) of the 80 oncologists
anonymously answered the questionnaire online (mean
age: 43.5 ± 7.8 years; women; 53.8 %; median years of
experience in NETs [p25-p75]: 9 [6–15]). Participants
were asked to rate each statement on a scale from 1 to 9
(1 = “completely disagree”; 9 = “completely agree”). Re-
sponses were grouped by tertiles: 1–3: Disagreement, 4–6:
Neutral, 7–9: Agreement. Consensus on a statement was
reached when the responses of ≥2/3 participants (≥66.6 %)
were located in the same tertile as the median value of all
the reported responses for that statement.
A second round of the Delphi questionnaire was
performed containing only the statements for which
consensus had not been reached in the first round and
statements with a neutral consensus, along with a sum-
mary of the responses for those statements in the first
round. Only the 65 oncologists who had responded the
questionnaire in the first round were invited to answer
the second round of the Delphi. From December 2015
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to January 2016, 57 (87.7 %) of the 65 oncologists
completed the second round of the questionnaire (mean
age: 42.8 ± 7.3 years; women; 56.1 %; median years of
experience in NETs [p25-p75]: 9 [6–14.5]).
Statistics
The median and interquartile range (p25-p75) of the an-
swers to every item of the questionnaire were calculated.
Cronbach’s alpha (Cα) was used to measure the
internal consistency of the questionnaire. Cα can range
between 0 and 1, from lower to greater reliability, with
values above 0.7 considered acceptable [24]. Intra-class
correlation coefficient (ri) was used to assess inter-rater re-
liability, which is considered as poor for ri values <0.40,
fair for ri: 0.40–0.59, good for ri: 0.60–0.74, and excellent
for ri: 0.75–1.0 [25]. The correlation between the two
rounds of the questionnaire was measured by the
Spearman coefficient (rs), which is considered as non-
existent when rs: 0–0.25, weak when rs: 0.26–0.50, moder-
ate to strong when rs: 0.51–0.75 and strong to very strong
when rs: 0.76–1 [26]. The Kappa index (k) was calculated
to estimate the qualitative agreement between the rounds
having into account the three answer groups (1–3, 4–6
and 7–9). Coherence is poor or inexistent when Kappa
index is < 0.20, weak from 0.21 to 0.40, moderate from
0.41 to 0.60, good from 0.61 to 0.80 and very good from
0.81 to 1 [27]. All these values were calculated for the
overall questionnaire and for each block. Statistical signifi-
cance was considered when p <0.05.
The variation coefficient (VC) of the questionnaire
was calculated for every round, along with the delta or
relative increase in the second round above the first
(VCsecond-VCfirst/VCfirst). When delta is <10 %, there is
no large variability between the rounds, and thus, there
is no need for another round.
Results
The questionnaire had good internal consistency (Cα
value >0.7 for the total questionnaire and each of the
blocks) and inter-rater reliability (ri value ≥0.7 for the
total questionnaire and each of the blocks) (Table 1).
Between the two rounds of the questionnaire, quanti-
tative correlation, as assessed by the Spearman coeffi-
cient, was acceptable, with values from moderate (rs >
0.5–0.75) to strong (rs > 0.76–1) for the questions that
were asked in both rounds (25) and for every block.
Qualitative agreement was also acceptable, with kappa
values from moderate (k > 0.4–0.6) to good (k > 0.6–0.8)
for the total 25 questions and for every block.
The VC in the first round was 0.38 ± 0.09 and in the
second 0.41 ± 0.09, which means a delta increase of
7.9 %; i.e. lower than 10 %, and thus, a third round was
not necessary.
Overall, consensus was obtained in 42 (36 agree-
ment and 6 disagreement) of the 48 statements
(87.5 %) (Tables 2, 3, 4, 5, and 6). In the first round,
there was consensus in 23 (47.9 %) statements (21
agreement and 2 disagreement) and non-consensus in 25
(52.1 %). Out of these 25, in the second round, there was
consensus in 19 (15 agreement and 4 disagreement) and
non-consensus in 6. The results observed in each CS are
discussed in the next section.
Discussion
A Delphi study was conducted to establish recommenda-
tions for the management of CS with undefined protocols
regarding the use of SSAs.
CS1 (Patient with non-functioning enteropancreatic
NET, non-susceptible to surgery or to loco-regional
treatment, and with Ki-67 < 10 %, ECOG ≤2, NON-
PROGRESSIVE in the last 3–6 months: Wait and
see vs. SSA treatment?)
Due to their proven benefits and tolerable safety pro-
file [11, 12, 28, 29], participants clearly agreed that this
type of patients should be treated with SSAs (even in
patients with stable disease) rather than considering a
wait and see strategy. In the CLARINET study (in which
95 % of the patients had stable disease at baseline)
median PFS was not reached in the lanreotide arm vs.
18.0 months (95 % CI: 12.1, 24.0) in the placebo arm
[12]. In the extension study, median PFS for patients
receiving lanreotide was 32.8 months (95 % CI: 30.9, 68)
[29]. Having stable disease before treatment is one of the
factors associated with tumor control with lanreotide in
patients with well-differentiated malignant digestive NETs
[30]. Additionally, a recent post-hoc analysis of the CLARI-
NET study has shown that lanreotide was associated with
improvements in tumour growth rates (% change in vol-
ume per month) vs. placebo as early as 12 weeks (treat-
ment difference: −2.9 [95 % CI: −5.1, −0.8]; p = 0.008) [31].
The experts also agreed that SSAs should be the treat-
ment of choice in patients with NET of digestive origin
and Ki-67 < 2 %, since almost every patient in the PROMID
Table 1 Internal consistency (Cα) and inter-rater reliability (ri) of
the Delphi questionnaire
Cα p-value ri p-value
TOTAL (48 items) 0.821 <0.001 0.808 <0.001
CS1 (9 items) 0.868 <0.001 0.792 <0.001
CS2 (16 items) 0.936 <0.001 0.891 <0.001
CS3 (9 items) 0.764 <0.001 0.722 <0.001
CS4 (6 items) 0.705 <0.001 0.673 <0.001
CS5 (8 items) 0.912 <0.001 0.885 <0.001
Bold data are the total
CS Clinical situation, Cα Cronbach’s alpha, ri Intra-class correlation coefficient
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study and two thirds of those in the CLARINET study had
a Ki-67 up to 2 %[11, 12].
However, a wait and see approach could also be con-
sidered (although the level of agreement was lower) in
patients with low tumor load, elderly patients or with
important comorbidities or patients with Ki-67 < 2 % (in
absence of other risk factors). No evidence-based data is
available with respect to overall survival (OS) to support
the early use of SSA vs. wait and see [11, 12, 32],
although it is difficult to obtain survival results in
patients with slow-growing tumors and long-life expect-
ancy. In any case, participants agreed that wait and see
should not be considered if Ki-67 > 5 %.
Currently, there is no clinical data regarding a potential
class effect of the two SSAs. Although this issue was not
directly addressed in the Delphi questionnaire, the partici-
pants agreed with lanreotide, and disagreed with octreotide,
being the SSA of choice in the treatment of patients with
NET of pancreatic origin and Ki67 > 2 % and <10 % (so far,
lanreotide is the only SSA with proven efficacy in pancre-
atic NETs [12]). In the recent ENETS guidelines update,
octreotide is recommended as medical first-line therapy in
patients with G1 advanced NETs, originated at midgut,
with positive somatostatin receptors and low tumor burden,
while lanreotide is recommended as medical first-line ther-
apy in patients with G1/G2 (<10 %) advanced NETs, origi-
nated at midgut or pancreas, with positive somatostatin
receptors and low or high (>25 %) liver tumor burden [33].
CS2 (Patient with non-functioning PANCREATIC
NET, non-susceptible to surgery or to loco-regional
treatment, and with Ki-67 < 10 %, ECOG ≤2: Treat-
ment initiation with SSA, MTD or chemotherapy?)
The participants agreed that SSAs monotherapy is the
treatment of choice in this patient in absence of high
tumor load and in the context of non-progressive dis-
ease, mainly due to the ease of use and low adverse ef-
fects of these drugs. In this regard, elderly patients with
these characteristics and presenting with important co-
morbidities are considered the most susceptible candi-
dates for SSA monotherapy. Patients receving SSA
monotherapy should be closely followed to detect pos-
sible early disease progression. The participants agreed
that lanreotide should be the SSA of choice in mono-
therapy in these cases, since it is the only SSA with
proven efficacy in pancreatic NETs [33] and patients in
the CLARINET study had ki-67 up to 10 % [12].
In the context of disease progression no consensus
was reached regarding the initial treatment of choice
(although almost 60 % of the participants consider the
use of SSA). According to recent ENETS guidelines [33],
SSAs may be of value in subgroups of patients with
slowly progressive G1 NETs of pancreatic origin, and
two prospective randomized trials in metastatic GEP-
NETs have shown antiproliferative effects after disease
progression [34, 35].
Table 2 Items regarding CS1: Patient with non-functioning enteropancreatic NET, non-susceptible to surgery or to loco-regional treatment,








median range n (%)
Result
1. Treatment is initiated with SSAs in most of this type of patients, since
available evidence shows that even in patients with stable disease,
treatment initiation significantly lengthens the time to progression.
8 (8–9) 7–9 58 (89.2) C - A
2. In the absence of other risk factors (younger age [<60–65 years],
important comorbidities or high Ki67), wait and see may be
considered in patients with low tumor load (hepatic ≤25 %).
30.8 %: 4–6 7 (4–8) 7–9 38 (66.7) C - A
3. In the absence of other risk factors (high Ki67 or extra-hepatic disease),
wait and see may be considered in fragile patients (with important
comorbidities/elderly [>75 years]).
8 (6–9) 7–9 47 (72.3) C - A
4. In the absence of other risk factors (younger age [<60–65 years],
important comorbidities or extra-hepatic disease) wait and see
may be considered in patients with low Ki-67 (<2 %).
32.3 %: 4–6 7 (6–8) 7–9 42 (73.7) C - A
5. Overall, wait and see is not considered in patients with Ki-67 > 5 %. 8 (7–9) 7–9 50 (76.9) C - A
6. Tumor localization (pancreatic or non-pancreatic) is not a key criterion
when deciding between wait and see or initiate treatment with SSAs.
63.1 %: 7–9 8 (7–8) 7–9 48 (84.2) C - A
7. Based on available evidence, lanreotide is the SSA of choice in the treatment
of patients with NET of pancreatic origin and Ki67 > 2 % and <10 %.
8 (7–9) 7–9 54 (83.1) C - A
8. Based on available evidence, octreotide is the SSA of choice in the treatment
of patients with NET of pancreatic origin and Ki67 > 2 % and <10 %.
40 %: 4–6 2 (2–3) 1–3 45 (78.9) C - D
9. Based on available evidence, SSAs are the treatment of choice in patients with
NET of digestive origin and Ki-67 < 2 %.
8 (7–9) 7–9 53 (81.5) C - A
CS Clinical situation, SSAs Somatostatin analogs, NET Neuroendocrine tumor, C consensus, NC non-consensus, A Agreement, D Disagreement
aOnly applies to statements with 2 rounds; participant % in median range: median range
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Table 3 Items regarding CS2: Patient with non-functioning PANCREATIC NET, non-susceptible to surgery or to loco-regional treatment,
and with Ki-67 < 10 %, ECOG ≤2: Treatment initiation with SSA, molecular targeted drugs or chemotherapy? [12, 36, 37, 63, 64]
CS Clinical situation, SSAs Somatostatin analogs, NET Neuroendocrine tumor, C consensus, NC non-consensus, A Agreement, D Disagreement, I Indeterminate
aOnly applies to statements with 2 rounds; participant % in median range: median range
Shadowed boxes: non-consensus
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Regarding MTDs, everolimus or sunitinib have shown
benefits in two placebo-controlled trials conducted in
patients with advanced pancreatic NETs with disease
progression [36, 37]. In the study by Raymond et al.,
patients randomized to sunitinib improved PFS and the
objective response rate vs. those receiving placebo [37].
An OS difference favouring sunitinib was observed, but
data from the 5 years follow-up was not significant
(although crossover might have confounded the results)
[38]. In the RADIANT-3 trial, patients randomized to
everolimus had longer median PFS than those random-
ized to placebo [36]. Additionally, the efficacy of everoli-
mus as first-line therapy was confirmed in the subgroup
of patients naive to chemotherapy [39].
Consensus agreement was reached on the safe com-
bination and potential additive effects of SSAs with
MTDs. This was suggested by the RADIANT-2 study,
although it was performed in patients with functioning
NETs [40]. In this double-blind, placebo-controlled,
phase 3 study comparing octreotide LAR alone with
octreotide LAR plus everolimus in patients with ad-
vanced, progressive NET with carcinoid symptoms, me-
dian PFS were 11.3 and 16.4 months, respectively (p =
0.026), failing to reach the level of pre-specified bound-
ary for significance (p ≤ 0.0246) [40]. However, “inform-
ative censoring” might explain this [41], since when
investigators determined that progression had occurred
the patient receiving octreotide LAR alone was allowed
to cross over to the combination group, but if central
review failed to confirm this progression, the patient was
censored resulting in inflating PFS values in the octreo-
tide LAR alone group.
Regarding patients with Ki-67 5–10 % and low tumor
load, the use of chemotherapy as initial treatment was
Table 4 Items regarding CS3: Patient with non-functioning GEP-NET, with Ki-67 < 10 %, ECOG ≤2, in treatment with anti-proliferative
dose of SSA and PROGRESSING: Is SSA treatment maintained? [13, 37, 40, 43, 44, 65–67]
CS Clinical situation, SSAs Somatostatin analogs, GEP Gastroenteropancreatic, NET Neuroendocrine tumor, C consensus, NC non-consensus, A Agreement, D
Disagreement, I Indeterminate
aOnly applies to statements with 2 rounds; participant % in median range: median range
Shadowed boxes: non-consensus
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Table 5 Items regarding CS4: Patient with non-functioning GEP-NET, non-susceptible to surgery or to loco-regional treatment, with
Ki-67 < 10 %, ECOG ≤2, AND NEGATIVE OCTREOSCAN®: Is SSA treatment initiated? [11, 48, 49, 68]
CS Clinical situation, SSAs Somatostatin analogs, GEP Gastroenteropancreatic, NET Neuroendocrine tumor, C consensus, NC non-consensus, A Agreement, D
Disagreement, I Indeterminate
aOnly applies to statements with 2 rounds; participant % in median range: median range
Shadowed boxes: non-consensus
Table 6 Items regarding CS5: Patient with non-functioning GEP-NET, non-susceptible to surgery or to loco-regional treatment, with








median range n (%)
Result
41. The use of SSA in monotherapy in these patients is reasonable
in patients with Ki-67 <20 %.
50.8 %: 7–9 7 (7–8) 7–9 48 (84.2) C - A
42. The use of SSA in monotherapy in these patients is reasonable in
case of low tumor load (hepatic ≤25 % and no extra-hepatic disease).
63.1 %: 7–9 8 (7–8) 7–9 50 (87.7) C - A
43. The use of SSA in monotherapy in these patients is reasonable in
case of NETs of gastrointestinal origin.
52.3 %: 7–9 7 (7–8) 7–9 49 (86) C - A
44. In case of important comorbidities, SSAs are an option in these patients. 8 (7–9) 7–9 56 (86.2) C - A
45. In these patients with Ki-67 from 10 to 20 % and/or high tumor load
(extra-hepatic and/or hepatic >25 %) and/or NET of pancreatic origin,
treatment is usually initiated with chemotherapy.
66.2 %: 7–9 7 (7–8) 7–9 48 (84.2) C - A
46. In these patients with Ki-67 from 10 to 20 % and/or high tumor load
(extra-hepatic and/or hepatic >25 %) and/or NET of pancreatic origin,
treatment is usually initiated with molecular targeted drugs (with the
possibility of combination with SSA).
7 (6–8) 7–9 45 (69.2) C - A
47. If discrepancy exists between the degree of cellular proliferation and the
octreoscan® results, it is recommended to perform 18FDG-PET-TAC to
help making a therapeutic decision.
53.8 %: 7–9 7 (7–8) 7–9 46 (80.7) C - A
48. If discrepancy exists between the degree of cellular proliferation and the
octreoscan® results, a re-biopsy of the growing lesions will be considered.
64.4 %: 7–9 7 (7–8) 7–9 53 (93) C - A
CS Clinical situation, SSAs Somatostatin analogs, GEP Gastroenteropancreatic, NET Neuroendocrine tumor, C consensus, NC non-consensus, A Agreement
aOnly applies to statements with 2 rounds; participant % in median range: median range
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rejected and a tendency towards rejecting the use of
MTDs was also observed. This probably suggests that
the use of SSAs in these patients is not uncommon. In
patients with Ki-67 5-10 % and high tumor load, the
participants agreed on initiating treatment with MTDs.
CS3 (Patient with non-functioning GEP-NET, with
Ki-67 < 10 %, ECOG ≤2, in treatment with anti-
proliferative dose of SSA and PROGRESSING: Is
SSA treatment maintained?)
The participants agreed on maintaining SSA in this
patient (mainly due to its good tolerability), independ-
ently of whether a MTD is added [42, 43]. Most studies
have shown a tendency for improved PFS in the combin-
ation arm vs. the single MTD arm, without reaching
statistical significance. In the RADIANT-2 study (func-
tioning NETs), patients who received everolimus/octreo-
tide LAR had longer median PFS than those who
received octreotide LAR alone, regardless of previous
SSA exposure [with previous exposure: PFS 14.3 months
(95%CI: 12.0–20.1) vs. 11.1 months (95 % CI: 8.4–14.6);
without: 25.2 months (95 % CI: 12.0-not reached) vs.
13.6 months (95 % CI: 8.2–22.7)] [44]. A subanalysis of
the Phase III sunitinib study conducted in patients with
advanced and progressing pancreatic NETs showed
improved PFS in patients receiving SSAs as compared to
those who did not, but it was not significantly different
[45]. Therefore, there was disagreement with statement
32 about withdrawing SSA when introducing a MTD. In
contrast, SSAs are usually withdrawn if chemotherapy is
started.
Additionally, the study participants consider increasing
the dose of the SSA, reducing the dose administration
interval or changing one SSA to the other in these patients.
CS4 (Patient with non-functioning GEP-NET, non-
susceptible to surgery or to loco-regional treatment,
with Ki-67 < 10 %, ECOG ≤2, AND NEGATIVE
OCTREOSCAN®: Is SSA treatment initiated?)
The octreoscan® result was rejected as an excluding
factor for the decision to administer SSA treatment,
since SSAs do not only exert an effect on hormone
secretion but have indirect antiproliferative effects,
which do not require the expression of all sybtypes of
somatostatine receptors [13, 46, 47]. In addition, the
octreoscan® may identify only a specific subtype of som-
atostatin receptor, such as type 2 [48]. In fact, patients
with negative octreoscan® have been shown to respond
to SSA [49], and patients with negative octreoscan® were
responsive in the PROMID study [11].
According to the results of sentences 39 and 40,
monotherapy with SSAs is not considered in patients
with negative octreoscan®, high tumor load and Ki67 >
5 %. A retrospective study in patients with digestive
NETs treated with lanreotide showed that Ki-67 ≤ 5 %
and hepatic tumor load ≤25 % were significantly associ-
ated with disease stability [30]. However, it must be
taken into account that the CLARINET study showed
the efficacy of lanreotide in tumors with Ki-67 up to
<10 %, and half of patients had >25 % liver involvement
and benefited from treatment [12].
Frequently, an octreoscan® result only considers
whether an uptake of the radiolabeled SSA has occurred
or not; however, the Krenning scale [lower than (grade
1), equal to (grade 2), or greater than (grade 3) normal
liver tissue; or higher than normal spleen or kidney up-
take (grade 4)] [50]] suggest that results considered as
negative could be positive.
CS5 (Patient with non-functioning GEP-NET, non-
susceptible to surgery or to loco-regional treatment,
with Ki-67>10 %, ECOG ≤2, AND POSITIVE
OCTREOSCAN®: Is SSA treatment initiated?)
A higher Ki-67 % is perceived as worse prognosis, and
thus, more aggressive treatment is recommended; there-
fore, in this patient SSA are usually combined with other
options.
The participants agreed that when Ki-67 is 10–20 %
(i.e., WHO grade 2 [51]), and/or there is high tumor
load and/or NET of pancreatic origin, treatment is usu-
ally initiated with MTDs (usually combined with SSA)
or chemotherapy. In the RADIANT-3 and RADIANT-4
studies, conducted in patients with progressive, ad-
vanced, pancreatic (RADIANT-3) or lung or gastrointes-
tinal (RADIANT-4) NETs, including intermediate-grade
tumors, everolimus resulted in significantly prolonged
PFS vs. placebo [36, 52], and the addition of octreotide
to everolimus was previously shown to be well tolerated
[42]. Other studies conducted in patients with advanced,
pancreatic NETs, including intermediate-grade tumors,
have achieved substantial clinical benefits with streptozo-
tocin and 5FU or doxorubicin, capecitabine and temozolo-
mide chemotherapy [53–55] or with oxaliplatin-based
chemotherapy [56–58]. In addition, platinum-based
chemotherapy resulted in a median survival of 11 months
in a study conducted in patients with G3 (Ki-67 > 20 %)
gastrointestinal neuroendocrine carcinoma, and survival
was significantly better in tumors of pancreatic origin than
colon origin [59].
The use of SSA in monotherapy could be considered
when Ki67 < 20 %, when there is low tumor load, and in
case of important comorbidities, since SSA results mainly
in tumor stabilization, and has low toxicity [34, 46, 60]. It
also seems reasonable in tumors of gastrointestinal origin,
since most of the evidence for chemotherapy and MTDs
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has been observed in tumors of pancreatic origin (al-
though >50 % of the patients in the everolimus arm in the
recent RADIANT-4 study had gastrointestinal NETs [52]).
Additionally, a 18FDG-PET-TAC or a re-biopsy can be
performed in case of discrepancy between the degree of
cellular proliferation and the octreoscan® results.
The study presented the limitations intrinsic to the
subjective nature of the answers. In addition, the number
of oncologists invited to participate was reduced (given
the low frequency of the disease), and thus, the number of
questionnaires evaluated was limited. However, the re-
sponse rate was high in both rounds of the questionnaire
(>80 %), and the results reflect clinical practice in the field
of NETs in Spain. Only the questions not reaching con-
sensus in the first round, along with those with neutral
consensus, were passed on to the second round in order
to shorten the time needed to answer the questionnaire,
to reduce participant fatigue [61]. The questionnaire
showed great internal consistency and high quantitative
and qualitative correlation between the two rounds for the
questions that needed the second round, and thus, the
answers may be considered reliable.
Conclusion
A series of recommendations based on the clinical prac-
tice and opinion of Spanish oncologists with experience
in the management of NETs were developed and may be
used as treatment guidance for the use of SSAs in
controversial NET CS.
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